Detailed Narrative
Strong Healthcare Segment Performance and Strategic Milestones
The Healthcare segment was the standout performer in Q4 FY26, with revenue doubling by 101% to INR 113 crores. For the full year FY26, healthcare revenue surged 139% to INR 393 crores, now contributing 40% of the consolidated revenue, up from 21% in FY25. A landmark achievement was the successful commercial launch of Shaily Harmony and Shaily Neo pen injectors for Semaglutide in India and global markets, including Canada. This marks entry into highly regulated pharmaceutical markets and validates the company's manufacturing standards.
Entry into Semiconductor Supply Chain and Consumer Electronics
Shaily has entered the semiconductor supply chain by signing a supply agreement with a Korean company for the manufacture and supply of semiconductor trays. Commercial supplies for this segment are expected to commence in Q4 FY27. Additionally, the company successfully commenced commercial supplies to a consumer electronics customer in Q4 FY26, marking a new growth vector. Management views consumer electronics as one of the two largest long-term opportunities alongside healthcare, with plans for an initial capex of INR 100 crores for a new plant down south.
Capacity Expansion and Operational Ramp-up for Pen Injectors
The company is actively ramping up its pen injector manufacturing capacity. An additional 25 million units of capacity for Semaglutide pens are expected to come online by July/August 2026. The existing 25 million capacity installed in March is currently running at approximately 45% utilization, with rejection rates reduced to 8%. The target is to achieve a combined capacity of 40-42 million pens from the two new lines by the end of FY27, with a broader target of 35-40 million pens in supply by end of FY28.
Financial Performance and Margin Improvement
For Q4 FY26, revenue stood at INR 237 crores (up 9% YoY) and EBITDA at INR 69 crores (up 27% YoY). EBITDA margin expanded by 420 bps to 29.3%. For the full year FY26, revenue reached INR 991 crores (up 26% YoY) and EBITDA grew 61% to INR 288 crores, with EBITDA margin at 29.0% (up 630 bps YoY). PAT for FY26 stood at INR 170 crores, an 83% increase YoY. Management expects margins to be sustainable and improving on a year-on-year basis.
Consumer Segment Headwinds and Industrial Growth
The Consumer segment experienced a degrowth of 31% in Q4 FY26 to INR 102 crores and 9% in FY26 to INR 511 crores, primarily due to weaker market demand for home furnishings in Europe and the U.S. Management anticipates a bounce back as global conditions improve. In contrast, the Industrial segment continued its growth trajectory, with revenues increasing 60% in Q4 FY26 to INR 22 crores and 41% in FY26 to INR 87 crores, driven by new business in power tools and LED lighting components.
Enabling Resolution for Fundraise and Capital Flexibility
The Board of Directors has approved an enabling resolution to raise up to INR 500 crores. This is intended to be an annual affair to maintain financial flexibility and ensure capital availability for high-quality, high-growth opportunities, rather than a specific fundraise plan. This disciplined approach ensures the company remains agile to seize compelling, time-sensitive opportunities, especially for potential substantial capex projects.